Group 1 - The stock of Xin Kai Yuan fell by 2.64% on August 27, with a trading volume of 457 million yuan [1] - On the same day, Xin Kai Yuan had a financing buy-in amount of 88.91 million yuan and a financing repayment of 79.23 million yuan, resulting in a net financing buy of 9.68 million yuan [1] - As of August 27, the total financing and securities lending balance of Xin Kai Yuan was 765 million yuan, with the financing balance accounting for 8.53% of the circulating market value, indicating a high level compared to the past year [1] Group 2 - Xin Kai Yuan Medical Technology Group Co., Ltd. was established on March 13, 2003, and listed on August 25, 2010, with its main business involving the research, production, and sales of PVP series products and other high-value pharmaceutical excipients [2] - The revenue composition of Xin Kai Yuan includes PVP series products (41.90%), PVPK30 (30.64%), and other diagnostic services, with a total revenue of 644 million yuan for the first half of 2025, a year-on-year decrease of 12.36% [2] - The net profit attributable to the parent company for the same period was 139 million yuan, down 34.74% year-on-year [2] Group 3 - Xin Kai Yuan has distributed a total of 900 million yuan in dividends since its A-share listing, with 607 million yuan distributed in the last three years [3]

财务报表中对有大幅变动的财务项目的原因说明如下： 据证券之星公开数据整理，近期新开源（300109）发布2025年中报。截至本报告期末，公司营业总收入 6.44亿元，同比下降12.36%，归母净利润1.39亿元，同比下降34.74%。按单季度数据看，第二季度营业 总收入3.19亿元，同比下降6.16%，第二季度归母净利润5853.64万元，同比下降36.06%。本报告期新开 源公司应收账款体量较大，当期应收账款占最新年报归母净利润比达86.53%。 本次财报公布的各项数据指标表现不尽如人意。其中，毛利率42.98%，同比减22.06%，净利率 21.41%，同比减26.36%，销售费用、管理费用、财务费用总计7509.54万元，三费占营收比11.66%，同 比减6.18%，每股净资产7.8元，同比增9.68%，每股经营性现金流0.15元，同比减52.92%，每股收益0.29 元，同比减35.56% | 项目 | 2024年中报 | 2025年中报 | 同比增幅 | | --- | --- | --- | --- | | 营业总收入(元) | 7.35 亿 | 6.44亿 | -12.36% | | 归母净利润 ...

Group 1 - The company did not distribute cash dividends or issue bonus shares during the reporting period [3] - The company’s controlling shareholder and actual controller did not change during the reporting period [5] - The company’s subsidiary, Beijing Liangyuan Biomedical Research Co., Ltd., received approval for clinical trials of a new drug for late-stage solid tumors [5][6] Group 2 - The company plans to distribute cash dividends of 2.493056 yuan per 10 shares, totaling approximately 121.18 million yuan, with the record date set for July 9, 2025 [5] - All directors attended the board meeting to review the report [2] - The company has ensured that the information disclosed is true, accurate, and complete [6]

证券代码：300109 证券简称：新开源 公告编号：2025-032 博爱新开源医疗科技集团股份有限公司 第五届董事会第十六次会议决议公告 经与会董事认真审议，会议形成了如下决议： （一）审议通过《关于 2025 年半年度报告及其摘要的议案》 董事会认为，公司 2025 年半年度报告全文及摘要的编制程序、内容和格式 符合法律、行政法规和中国证监会的有关规定，报告内容真实、准确、完整地反 映了公司 2025 年半年度的实际情况，不存在任何虚假记载、误导性陈述或者重 大遗漏。 公司董事会审计委员会已审议通过本议案。 公司监事会对本议案发表了审核意见。 本公司及其董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、董事会会议召开情况 博爱新开源医疗科技集团股份有限公司（以下简称"公司"或"新开源"） 第五届董事会第十六次会议于 2025 年 8 月 25 日上午在公司三楼会议室以现场加 通讯的表决方式召开，本次会议通知已于 2025 年 8 月 13 日以电子邮件形式发出。 本次会议由公司董事长张军政先生主持，应出席董事 9 名，实际出席董事 9 名，公司部分监事和高级管理人员列 ...

Group 1 - The meeting of the fifth supervisory board of Boai Xinkaiyuan Medical Technology Group Co., Ltd. was held on August 25, 2025, with all three supervisors present [1][2] - The supervisory board approved the procedures for the preparation and review of the 2025 semi-annual report and its summary, confirming compliance with relevant laws and regulations [1] - The report content was deemed to accurately and completely reflect the actual situation of the listed company, with no false records or misleading statements [1]

（文章来源：证券日报） 证券日报网讯 8月26日晚间，新开源发布公告称，公司第五届董事会第十六次会议审议通过了《关于 2025年半年度报告及其摘要的议案》。 ...

（编辑 何成浩） 证券日报网讯 8月26日晚间，新开源发布公告称，2025年半年度公司实现营业收入644，014，332.79 元，同比下降12.36%；归属于上市公司股东的净利润为138，956，706.00元，同比下降34.74%。 ...

证券日报网讯 8月26日晚间，新开源发布公告称，公司第五届监事会第十二次会议审议通过了《关于 2025年半年度报告及其摘要的议案》。 （文章来源：证券日报） ...

| | 本报告期 | 上年同期 | | --- | --- | --- | | 营业收入(元) | 644, 014, 332. 79 | 734,804,462.96 | | 归属于上市公司股东的净利 | 138, 956, 706. 00 | 212, 929, 814. 26 | | 润(元) | | | | 归属于上市公司股东的扣除 非经常性损益的净利润 | 129, 317, 734. 25 | 218, 300, 190. 74 | | (元) | | | | 经营活动产生的现金流量净 | 74, 385, 132. 17 | 158, 165, 912. 48 | | 额(元) | | | | 基本每股收益(元/股) | 0. 29 | 0. 45 | | 稀释每股收益(元/股) | 0. 29 | 0. 44 | | 加权平均净资产收益率 | 3.75% | 5.91% | | | 本报告期末 | 上年度末 | | 总资产(元) | 4, 695, 242, 883. 74 | 4, 372, 054, 795. 55 | | 归属于上市公司股东的净资 | 3, 778, 561, 272. ...

今日，有消息称智谱 GLM-4.5，OpenAI的全球竞争对手，将于今晚发布新开源模型。对此，有知情人 士透露，今晚会发布，是有这个事情的。（新浪科技） ...